Mumbai, July 6 -- Glenmark Pharmaceuticals Inc., USA (Glenmark) announced the launch of Olanzapine for Injection, 10 mg/vial, Single-Dose Vial. Glenmark's Olanzapine for Injection is bioequivalent and therapeutically equivalent to the reference listed drug, Zyprexa(R)2 IntraMuscular Injection 10 mg/vial, of Cheplapharm Registration GmbH [NDA 021253].

Published by HT Digital Content Services with permission from Capital Market....